Lilly(Eli) & Co

LLY

$336.13

+18.5% last 12 months

Ken Fisher Holding value: $1.34 Billion Ken Griffin Holding value: $331 Million Jeremy Grantham Holding value: $261 Million Jim Simons Holding value: $260 Million Stanley Druckenmiller Holding value: $248 Million Ray Dalio Holding value: $77.6 Million Mario Gabelli Holding value: $10.4 Million Joel Greenblatt Holding value: $1.24 Million Steven Cohen Holding value: $0 Julian Robertson Holding value: $0 Tom Russo Holding value: $0 Chris Davis Holding value: $0 George Soros Holding value: $0 Bill Gates Holding value: $0 David Tepper Holding value: $0

Market Cap

$316 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$273.35 - $383.20

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

50.62x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$4.05 (1.22%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $316 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $330 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $4.05 (1.22%)
1 Year Return Profit or loss of share price change plus dividend yield. +19.8%
52-Week High Highest share price in the last 52 weeks. $383.20
52-Week Low Lowest share price in the last 52 weeks. $273.35
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.47
Outstanding Shares The number of shares the company has issued and are held by stockholders. 950 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 3.61 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 50.62
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 412.92
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $6.90
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 11.2
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 30.56
Enterprise Value to Revenue Enterprise value divided by revenue 11.57
Enterprise Value to EBIT Enterprise Value divided by EBIT 39.87
Total Debt to Enterprise Value Total debt divided by enterprise value 0.05
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.52

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $28.5 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $21.9 Billion
EBIT Earnings before tax and interest payments. $8.28 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $6.24 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 21.88%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +12.3%
Return on Equity Equity divided by market cap. 58.64%
Return on Assets Indicates a company's profitability in relation to its total assets. 12.62%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 25.60%

Insider trades

No purchases

376,175.0 shares sold (20 transactions)

No purchases

52,138.0 shares sold (1 transactions)

No purchases

No sells

No purchases

No sells

Q2 2022 Q3 2022 Q4 2022 Q1 2023

About Lilly(Eli) & Co

CEO: David Ricks

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Merck & Co Inc
Merck & Co Inc
Johnson & Johnson
Johnson & Johnson
Pfizer Inc.
Pfizer Inc.
Sanofi - ADR
Sanofi - ADR
GSK Plc - ADR
GSK Plc - ADR
Abbvie Inc
Abbvie Inc
AMGEN Inc.
AMGEN Inc.
Novartis AG - ADR
Novartis AG - ADR
Astrazeneca plc - ADR
Astrazeneca plc - ADR

News

AOC criticizes Elon Musk for plans to remove Twitter’s legacy blue checkmarks on April Fool’s day

AOC criticizes Elon Musk for plans to remove Twitter’s legacy blue checkmarks on April Fool’s day

Rep. Alexandria Ocasio-Cortez criticized Twitter''s plans to scrap legacy blue checkmarks. Elon Musk''s company announced it was revoking legacy verified che...

Business Insider Nederlands Business Insider Nederlands, 1 day ago
Will Eli Lilly Be a Trillion-Dollar Stock by 2030?

Will Eli Lilly Be a Trillion-Dollar Stock by 2030?

Should you buy shares of this pharmaceutical giant now?

The Motley Fool The Motley Fool, 3 days ago
Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

84% of Eli Lilly''s shares are held by 3370 institutional investors. See why LLY is the best near-term pharma stock to Buy now.

Seeking Alpha Seeking Alpha, 3 days ago
Lilly, Roche team up to develop blood test for Alzheimer''s disease

Lilly, Roche team up to develop blood test for Alzheimer''s disease

Eli Lilly (LLY) and Roche (RHHBY) (RHHBF) are collaborating to develop a blood test for detecting Alzheimer''s disease ((AD)).The companies will develop Roch...

Seeking Alpha Seeking Alpha, 4 days ago
Never miss a trade
To improve your user experience we use cookies.